Table 3.

Clinical features of BL and DLBCL in dmCODOX-M/IVAC and pathology studies

		BL		DLBCL		Total
		n	%	n	%	n	%
Age, y
CODOX-M/IVAC*	60 or less	48	91	38	67	86	78
	61 to 65	2	4	7	12	9	8
	More than 65	2	4	12	21	15	14
	Total	53	100	57	100	110	100
	Median (range)	37	(17-76)	55	(19-78)	42	(17-78)
Both*	60 or less	52	90	41	59	93	73
	61 to 65	2	3	10	14	12	9
	More than 65	4	7	19	27	23	18
	Total	58	100	70	100	128	100
	Median (range)	37	(17-76)	56	(19-83)	43	(17-83)
Sex
CODOX-M/IVAC	Male	42	79	42	74	84	76
	Female	11	21	15	26	26	24
	Total	53	100	57	100	110	100
Both	Male	46	79	46	66	92	72
	Female	12	21	24	34	36	28
	Total	58	100	70	100	128	100
LDH level
CODOX-M/IVAC	Normal	9	17	18	32	27	25
	Raised	44	83	39	68	83	75
	Total	53	100	57	100	110	100
Both	Normal	12	21	21	30	33	26
	Raised	46	79	49	70	95	74
	Total	58	100	70	100	128	100
WHO PS
CODOX-M/IVAC	0	18	34	15	26	33	30
	1	15	28	16	28	31	28
	2	8	15	15	26	23	21
	3	10	19	10	18	20	18
	4	2	4	1	2	3	3
	Total	53	100	57	100	110	100
Both	0	20	34	18	26	38	30
	1	17	29	19	27	36	28
	2	9	16	18	26	27	21
	3	10	17	13	19	23	18
	4	2	3	2	3	4	3
	Total	58	100	70	100	128	100
Ann Arbor stage
CODOC-M/IVAC	I	7	13	12	21	19	17
	II	6	11	12	21	18	16
	III	4	8	5	9	9	8
	IV	36	68	28	49	64	58
	Total	53	100	57	100	110	100
Both	I	10	17	14	20	24	19
	II	6	10	16	23	22	17
	III	5	9	7	10	12	9
	IV	37	64	33	47	70	55
	Total	58	100	70	100	128	100
No. of extranodal sites of disease
CODOX-M/IVAC	1 or less	26	49	34	60	60	55
	More than 1	27	51	23	40	50	45
	Total	53	100	57	100	110	100
Both	1 or less	29	50	43	61	72	56
	More than 1	29	50	27	39	56	44
	Total	58	100	70	100	128	100
Modified IPI score
CODOX-M/IVAC*	0	7	13	15	26	22	20
	1	6	11	8	14	14	13
	2	22	42	12	21	34	31
	3	18	34	22	39	40	36
	Total	53	100	57	100	110	100
Both*	0	10	17	17	24	27	21
	1	6	10	11	16	17	13
	2	23	40	15	21	38	30
	3	19	33	27	39	46	36
	Total	58	100	70	100	128	100
Risk group
CODOX-M/IVAC	Low risk	11	21	22	39	33	30
	High risk	42	79	35	61	77	70
	Total	53	100	57	100	110	100
Both	Low risk	14	24	27	39	41	32
	High risk	44	76	43	61	87	68
	Total	58	100	70	100	128	100
CNS
CODOX-M/IVAC	Not involved	47	89	48	87	95	88
	Involved	6	11	7	13	13	12
	Unknown	0		2		2
	Total	53	100	57		110
Both	Not involved	50	88	60	90	110	89
	Involved	7	12	7	10	14	11
	Unknown	1		3		4
	Total	58		70		128
Marrow
CODOX-M/IVAC	Not involved	29	55	40	71	69	63
	Involved	24	46	16	29	40	37
	Unknown	0		1		1
	Total	53	100	57		110
Both	Not involved	32	56	52	76	84	67
	Involved	25	44	16	24	41	33
	Unknown	1		2		3
	Total	58		70		128
GI involved (ileocaecal, stomach)
CODOX-M/IVAC	Not Involved	35	67	44	79	79	73
	Involved	17	33	12	21	29	27
	Unknown	1		1		2
	Total	53		57		110
Both	Not involved	39	70	54	79	93	75
	Involved	17	30	14	21	31	25
	Unknown	2		2		4
	Total	58		70		128
B symptoms
CODOX-M/IVAC	No	18	35	35	63	53	49
	Yes	34	65	21	38	55	51
	Unknown	1		1		2
	Total	53		57		110
Both	No	21	38	39	57	60	48
	Yes	35	63	29	43	64	52
	Unknown	2		2		4
	Total	58		70		128
Preinduction chemo given
CODOX-M/IVAC*	No	35	66	38	67	73	66
	CHOP	7	13	10	18	17	15
	COP	0	0	1	2	1	1
	Other	11	21	8	14	19	17
	Total	53	100	57	100	110	100
Both*	No	38	67	50	72	88	70
	CHOP	7	12	10	14	17	13
	COP	0	0	1	1	1	1
	Other	12	21	8	12	20	16
	Unknown	1		1		2
	Total	58		70		128

^*CODOX-M/IVAC indicates those patients entered into dmCODOX-M/IVAC study only; Both indicates the total patients included in dmCODOX-M/IVAC or pathology study.